Delivery of RNA to Trigger Multiple Immune Pathways
GlaxoSmithKline Biologicals S.A.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 18 of these applications claim priority to application PCT/US2011/043104, filed Jul 6, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,532,067 | Delivery of RNA to Trigger Multiple Immune Pathways In force · High confidence UsedRemaining | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,291,682 | Delivery of RNA to Trigger Multiple Immune Pathways In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,324,770 | Delivery of RNA to Trigger Multiple Immune Pathways In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,596,645 | Delivery of RNA to Trigger Multiple Immune Pathways In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 12,186,333 | Delivery of RNA to Trigger Multiple Immune Pathways In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 9,801,897 | Delivery of RNA to Trigger Multiple Immune Pathways In force · High confidence | GlaxoSmithKline Biologicals S.A. | In force | High confidence | ||
| US 11,690,861 | Delivery of RNA to Trigger Multiple Immune Pathways In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,690,862 | Delivery of RNA to Trigger Multiple Immune Pathways In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,690,863 | Delivery of RNA to Trigger Multiple Immune Pathways In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| US 11,690,864 | Delivery of RNA to Trigger Multiple Immune Pathways In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | ||
| 9 more records in this group · Pro | ||||||
10 of 19 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 19.
18 of these are in force and held by GlaxoSmithKline Biologicals S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.